Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02648711
Title Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cerulean Pharma Inc.
Age Groups: adult
Covered Countries USA

No variant requirements are available.